Silence Therapeutics develops siRNA-based medicines targeting genetic diseases, focusing on hematology, cardiovascular disease, and rare diseases, based on its mRNAi GOLD™ platform.

Silence Therapeutics

Domain Not Resolving

HSTS

DNSSEC

HSTS IncludeSubdomains PreLoad

Microsoft

COVID-19

Vimeo

Microsoft Azure

Apple Whitelist

Cloudflare SSL

President and Chief Executive Officer

Craig Tooman

Exec Chair at Oxehealth & OXECO

James Ede-Golightly

Chief Financial Officer

Rhonda Hellums

SVP, Chief Intellectual Property and Innovation Officer

Barbara Ruskin

Vice President Clinical Sciences

Curtis Rambaran

VP, Head of Clinical Operations

Hannah Barry

SVP, Business Development, Alliance Management and New Product Development

John Strafford

VP, Head of HR

Linnea Elrington

SVP, Head of Molecular Design

Marie Lindholm

Director, Head of FP&A

Clare Elliott

Dmitry Samarsky

Chief Scientific Officer

Steve Romano

Chief Medical Officer and Head of Research and Development

Michael Davidson

Non-Executive Director

John Paul Gabriel

Chief Technical Operations Officer and Senior Vice President

Non Executive Director

Adrien Weingärtner

Group Leader Drug Delivery

SVP, Head of Business Development, Alliance Management and New Product Development

Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.

England Health Care Companies

Medical Public Companies With Less Than $1B in Revenue

Europe, Middle East, and Africa (EMEA) Medical Companies (Top 10K)

Health Care Companies With More Than 100 Employees (Top 10K)

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.

Post-IPO Equity - Silence Therapeutics

Frazier Healthcare Partners

Mallinckrodt

London

England

United Kingdom

Europe

SILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes

Silence Therapeutics weakness after AHA updates 'overdone,' says BMO Capital

Top 3 Health Care Stocks You'll Regret Missing In Q4

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Redburn Atlantic semiconductor analyst holds an analyst/industry conference call

Silence Therapeutics presents late-breaking Phase 2 zerlasiran data at AHA

European Equities Traded in the US as American Depositary Rise in Monday Trading

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Analyst Scoreboard: 4 Ratings For Silence Therapeutics

Silence Therapeutics reports Q3 results (SLN:NASDAQ)

A proprietary platform that uses RNA interference to target and silence disease-associated genes without altering DNA.

An siRNA therapy in development for reducing high lipoprotein(a) levels, a cardiovascular risk factor.

An siRNA therapy targeting TMPRSS6 to manage iron levels and treat polycythemia vera by increasing hepcidin.

United States

North America

France

Pakistan

Asia

Greece

Indonesia

HTML5

Microsoft Outlook

GoDaddy

Adobe Flash

Amazon Route 53

Google Fonts

Amazon EC2

Cloudflare CDN

Google Maps API

Wordpress

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Silence Therapeutics plc

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 23, 2024 9:07 PM	c789b0ca
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 23, 2024 9:07 PM	a9b2a531
crunchbase trigger	general	Nov 22, 2024 7:44 AM	dbb7f88a
crunchbase profile	general	Nov 22, 2024 3:26 PM	da3fcc10
li profile	general
translate crunchbase fundingrounds	general	Nov 23, 2024 1:19 AM	25d648f7
peers	general	Sep 23, 2024 9:07 PM	cd43f0ed
news basic	general	Sep 23, 2024 9:07 PM	9b9a4dee
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:SILENCE-THERAPEUTICS

Silence Therapeutics

Last Close

540.00

01/01 00:00

Volume Today

913.53K

Avg: -